Additionally, the percentage time in target range was 64.06%, suggesting that the model-maintained glucose within the clinically safe range for a majority of the time.<h4>Conclusions</h4>The DQN-based RL model demonstrated its effectiveness in personalized insulin dosing while minimizing the risk of hypo- and hyperglycemia. The gene discussed is INS; the disease is Hyperglycemia.